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Abstract
Background: Glioblastoma (GBM) is an aggressive malignant brain tumor
where median survival is approximately 15 months after best available mul-
timodal treatment. Recurrence is inevitable, largely due to O6 methylguanine
DNA methyltransferase (MGMT) that renders the tumors resistant to temo-
zolomide (TMZ). We hypothesized that pretreatment with bortezomib (BTZ)
48 hours prior to TMZ to deplete MGMT levels would be safe and tolerated by
patients with recurrent GBM harboring unmethylated MGMT promoter. The
secondary objective was to investigate whether 26S proteasome blockade may
enhance differentiation of cytotoxic immune subsets to impact treatment re-
sponses measured by radiological criteria and clinical outcomes.
Methods: Ten patients received intravenous BTZ 1.3 mg/m2 on days 1, 4, and
7 during each 4th weekly TMZ‐chemotherapy starting on day 3 and escalated
from 150mg/m2 per oral 5 days/wk via 175 to 200mg/m2 in cycles 1, 2, and 3,
respectively. Adverse events and quality of life were evaluated by CTCAE and
EQ‐5D‐5L questionnaire, and immunological biomarkers evaluated by flow
cytometry and Luminex enzyme‐linked immunosorbent assay.
Results: Sequential BTZ + TMZ therapy was safe and well tolerated. Pain and
performance of daily activities had greatest impact on patients' self‐reported
quality of life and were inversely correlated with Karnofsky performance sta-
tus. Patients segregated a priori into three groups, where group 1 displayed
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stable clinical symptoms and/or slower magnetic resonance imaging radi-
ological progression, expanded CD4+ effector T‐cells that attenuated cytotoxic
T‐lymphocyte associated protein‐4 and PD‐1 expression and secreted inter-
feron γ and tumor necrosis factor α in situ and ex vivo upon stimulation with
PMA/ionomycin. In contrast, rapidly progressing group 2 patients exhibited
tolerised T‐cell phenotypes characterized by fourfold to sixfold higher inter-
leukin 4 (IL‐4) and IL‐10 Th‐2 cytokines after BTZ + TMZ treatment, where
group 3 patients exhibited intermediate clinical/radiological responses.
Conclusion: Sequential BTZ + TMZ treatment is safe and promotes Th1‐
driven immunological responses in selected patients with improved clinical
outcomes (Clinicaltrial.gov (NCT03643549)).
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1 | INTRODUCTION
Glioblastoma (GBM) is the most prevalent and aggressive
brain tumor in humans. Standard first‐line treatment for
fit patients consists of surgery aiming for maximal safe
tumor resection,1,2 followed by radiochemotherapy with
daily temozolomide (TMZ) administered concomitantly
with external beam fractionated ionizing radiation for 6
weeks to a total dose of 60 Gy in 30 fractions. Adjuvant
TMZ is administered for 5 days every 4th week for up to
six cycles.3 Despite this multimodal treatment, median
overall survival is only approximately 15 months.3‐5 For
patients harboring GBM with unmethylated O6 methyl-
guanine DNA methyltransferase (MGMT) promoter,
2‐year survival rate is only 14% compared to 46% for those
with methylated MGMT promoter6 and thus, MGMT
promoter status is both prognostic and predictive of
treatment response to TMZ chemotherapy. Tumor re-
currence is inevitable and median time to neoplastic
progression is approximately 6.9 months.3 There is no
standard treatment after recurrence, therefore, options
are dependent on physician's choice or practice at the
given institution. The European society for medical on-
cology guidelines recommend that patients be treated
within investigational protocols.7
Profound cellular and molecular heterogeneity ty-
pifies GBM8,9 thus, combination therapy to mitigate drug
resistance has become the benchmark of neuro‐oncology.
Nevertheless, the alkylating chemotherapeutic agents,
temozolomide and lomustine are still the backbone of
systemic glioma therapy.10 Several clinical studies have
explored blocking of MGMT to improve TMZ efficacy in
treatment resistant GBM.11‐14 Transcription factors and
coactivators, including nuclear factor κB (NF‐κB),15
tumor protein 53 (TP53),16,17 transcription factor Sp1,16
hypoxia inducible factor‐1α (HIF‐1α),18 cyclic adenosine
monophosphate response element‐binding protein,19
MGMT enhancer binding protein20 and signal transducer
and activator of transcription 3 (STAT3)21 have also been
investigated for their potential to regulate MGMT protein
expression. It has been established that NF‐κB binding
sites are present within the MGMT promoter region, that
MGMT messenger RNA (mRNA) is induced by NF‐κB/
p65, and that MGMT expression correlates with NF‐κB
activation regardless of promoter methylation status.15,22
NF‐κB activation requires 26S proteasomal processing.23
Bortezomib (BTZ) is a proteasome inhibitor that has
been approved for treatment of multiple myeloma, mantle
cell lymphoma and trialed in early phase trials for treat-
ment of GBM. It blocks the chymotryptic activity of the 26S
proteasome and prevents degradation of misfolded proteins
or abundant short‐lived proteins such as transcription fac-
tors that may be important in regulation of tumor and
immune cell differentiation, proliferation, and apoptosis.
We recently showed that GBM pretreatment with BTZ for
48 hours prohibited phosphorylation of IkBα, resulting in
reduced nuclear translocation of the activated phosphory-
lated NF‐κB p65/RelA subunit. This correlated with re-
duced MGMT protein and mRNA expression by 70%‐80%
and sensitized the GBM cells to TMZ chemotherapy.22 Two
other studies also investigated MGMT depletion via me-
chanisms associated with activation of NFκB, MAPK,
STAT3, and HIF‐1α pathways after BTZ treatment.16,18 As
well as depleting the tumor's cytoprotective mechanisms,
agents that simultaneously promote tumor recognition by
cells of the immune system may be attractive anticancer
candidates. Indeed, we demonstrated that natural killer
(NK) cells treated with BTZ exhibited more mature,
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activated and cytotoxic CD57+CD16dimCD69+ phenotype,
and that efficacy of combination treatment of GBM cells
with BTZ+NK cells in vitro and in vivo was augmented by
tumor necrosis factor related ligand (TRAIL)‐receptor in-
teractions, as well as tumor expression of stress‐ligands re-
cognized by activating NKG2D receptor.24 Sequential
combination of BTZ 48 hours before TMZ 164mg/m2
treatment, depleted MGMT mRNA in vivo, attenuated tu-
mor growth and significantly prolonged animal survival.22
Thus, this phase IB of our BORTEM‐17 clinical trial
(NCT03643549) was launched to investigate whether pre-
treatment of recurrent GBM patients with BTZ 1.3mg/m2
on days 1, 4, and 7, to deplete MGMT levels 48 hours before
TMZ, commencing on days 3 to 7 every 4th week, might
sensitize MGMT unmethylated GBM to TMZ chemother-
apy. We assessed the maximal safe escalated TMZ dose
administered in sensitization schedule with BTZ and
whether treatment enhanced differentiation of cytotoxic
immune subsets to impact treatment responses.
2 | MATERIALS AND METHODS
2.1 | Treatment plan
The study protocol (Figure 1A) was approved by the regional
ethical board for Western Norway (2017/2084) and the
Norwegian Medicines Agency (17/17445‐17). All eligible
patients signed the approved consent form for study parti-
cipation before undergoing any study related procedures.
Inclusion/exclusion criteria are summarized in the Support-
ing Information and further details available on: https://
clinicaltrials.gov/ct2/show/NCT03643549?term=Bortezomib
+and+temozolomide&cond=GBM&draw=2&rank=1
FIGURE 1 Schematic of trial schedule. A, Timeline showing BORTEM‐17 treatment regimen. Bortezomib administered
intravenous at days 1, 4, and 7 (48 hours pretreatment to deplete MGMT protein) before target TMZ 200mg/m2 dose for 5 days (from
and including days 3‐7), repeated in six cycles. In n= 3 patients per each dose 150 vs 175 vs 200 mg/m2 TMZ in dose pathfinding,
safety evaluation. Clinical chemistry for renal, hepatic, and bone marrow monitoring for toxicity based on CTCAE v. 4.03. MRI
tumor monitoring radiological response assessment based on RANO criteria. Rationale for sequential treatment schedule based on
preclinical data. B, sequential administration in BORTEM‐17 clinical trial vs (C) previous studies where BTZ on days 1, 4, 8, and 11
was given concomitantly with TMZ from day 1 to 5, when MGMT levels were high. Dashed boxes mark days when TMZ doses might
be more effective, (B) all five doses vs (C) three doses every month. BTZ, bortezomib; CBC Diff, complete blood count with
differential test; CMP, comprehensive metabolic panel; KPS, Karnofsky performance score; LFT, liver function test; MGMT, O6‐
methyl guanine DNA methyltransferase; MRI, magnetic resonance imaging; NANO, neurologic assessment in neuro‐oncology; QoL,
quality of life; TMZ, temozolomide
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Ten patients (n = 8 males and n = 2 females) were
enrolled between September 2018 and October 2019
and their characteristics are summarized in Table 1.
BTZ 1.3 mg/m2 was administered as 30 seconds bolus
intravenous injection on days 1, 4, and 7 during each
4th week chemotherapy cycle. The first three patients
received 150 mg/m2 TMZ per oral 5 days/wk starting
on day 3 after BTZ administration in the first cycle
and thereafter 175 and 200 mg/m2 every 4 weeks in
cycles 2 and 3, respectively (Figure 1A). If all three
patients at a given TMZ dose did not develop a dose
limiting toxicity (ie, grade 3 or 4 on Common Termi-
nology Criteria for Adverse Events [CTCAE]), the next
cohort of three patients would be treated at the next
TMZ dose level. The ultimate aim was to attain com-
bination treatment with BTZ and TMZ at 200 mg/m2
which was closest to the most effective dose in the
preclinical study.22 Total treatment duration per
patient was estimated for 6 to 12 months unless
disease progression.
2.2 | NeuroImaging
Brain magnetic resonance imaging (MRI) was performed
using the 3T Siemens MAGNETOM Prisma (Siemens
Healthineers, Munich, Germany) at the Radiology
Department at Haukeland University Hospital (details of
sequences and quantification of radiologic tumor growth
are reported in the Supporting Information). MRI was
undertaken no earlier than 2 weeks before enrollment to
confirm disease progression using T2 and T1 MRI se-
quences with and without gadolinium contrast agent
(Clariscan; GE Healthcare) and reported by the study
neuroradiologist based on RANO criteria.25 MRI was also
undertaken at day 56, after two cycles of BTZ and TMZ
treatment, and thereafter every 8th week until endpoint
evaluation at 6 months.
2.3 | Clinical evaluation and
self‐reported quality of life
Clinical evaluation including neurological assessment
according to Neuro‐Oncology (NANO) scale,26 EQ‐5D‐5L
quality of life questionnaire,27 and Karnofsky perfor-
mance status (KPS) were recorded during consulta-
tions every 4th week and before MRI evaluations.
Hematological tests were obtained within 1 week of
study enrollment and subsequently within each treat-
ment cycle on days 1, 4, 7, 11, 15, 22, and 28 before
commencing the next cycle. Molecular pathology in-
cluding MGMT promoter methylation, IDH1, TP53,
and ATRX mutation analysis was undertaken at the
pathology department. Adverse events were graded
using the National Cancer Institute CTCAE
version 4.03.
2.4 | Immune monitoring
Immune monitoring was performed on peripheral blood
mononuclear cells (PBMCs) before, during and after
BTZ+ TMZ treatment in time course analyses on day 1,
4, 7, 11, 15, and 22 of the first treatment cycle. PBMCs
were stained with fluorescent conjugated primary anti-
body mix for NK and T cells (Table S1 and Figure S1),
data acquired on BD LSR FORTESSA (BD Biosciences,
Trondheim, Norway) and analysed with FlowJo software
version 10 (Tree Star Inc, Ashland, OR) as detailed in the
Supporting Information.
2.5 | Statistical analysis
Linear mixed effects model regression analysis was used
to analyse tumor volumes, EQ‐5D‐5L health scores and
their correlation with NANO scores and ability to predict
KPS throughout the course of treatment using Stata
version 15.1 (StataCorp LLC, Texas). One‐ and two‐way
analysis of variance (ANOVA) with Bonferroni correction
for multiple testing was used to analyse im-
munomonitoring and enzyme‐linked immunosorbent
assay data using Graphpad PRISM 8.0 software (La Jolla,
CA). Two‐sided P values less than .05 were considered
significant.
3 | RESULTS
3.1 | BORTEM‐17 trial schedule
Our treatment regimen was based on a previous pre-
clinical study where we demonstrated that BTZ pre-
treatment of GBM cells for 48 hours depleted MGMT
levels and sensitized to TMZ. Thus, the sequential sche-
dule was adopted, administering intravenous bolus
1.3 mg/m2 BTZ on days 1, 4, and 7 before target TMZ
200mg/m2 dose for 5 days (starting from and including
days 3‐7), repeated in six cycles (Figure 1A). Previous
studies had administered BTZ on days 1, 4, 8, and 11,
where this was concomitantly administered with TMZ
from day 1 to 5 (when MGMT levels would be high the
first 2 days in MGMT unmethylated patients). Our ra-
tionale was thus to maximize the therapeutic potential
of all five TMZ doses by only administering the
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chemotherapy 48 hours after BTZ when MGMT levels
would be lowest (Figure 1B,C).
3.2 | BORTEM‐17 patient characteristics
The basic clinical and molecular characteristics of the
patients are indicated in Table 1. Our patient cohort in-
cluded eight males and two females with a median age of
49 years (range, 26‐58) and median KPS score 80 (range,
80‐100) at enrollment. In accordance with the inclusion
criteria, all patients had unmethylated MGMT promoter
(quantitatively <4% methylation), while n= 4/10 (40%)
were IDH1 R132H mutant with accompanying TP53
and ATRX mutations. Five patients possessed the
KIR2DS4*00101 allele as homozygous or heterozygous
alleles that we previously demonstrated to be an in-
dependent good prognostic factor.28 At the time of pri-
mary diagnosis, five patients had undergone gross total
resection while the remaining five had subtotal resection
or biopsy. Primary tumor location was temporal (2/10),
frontal (3/10), parietal lobes (3/10), and in two patients
multifocal. Seven patients (70%) were enrolled onto the
study protocol after their second recurrence and three of
them had had secondary surgery. Three patients were
treated at first tumor recurrence.
3.3 | BTZ administered in combination
with TMZ is appropriately metabolized
Next, we investigated time course pharmacokinetic dis-
tribution of BTZ after administration to establish that in
these heavily pretreated GBM patients, BTZ was meta-
bolized as previously described.29 The plasma con-
centration of BTZ showed a biphasic decline, with a fast
distribution phase and a slower elimination phase con-
sistent with a two‐compartment model (Figure 2A).
There was also an increase in plasma concentrations at
all time‐points on day 7 where estimated Cmax was twice
as high, (P< .001; Figure 2A and Table 2) compared to
day 1. Both the increased Cmax and area under the curve
values (ng/mL) were consistent with previous findings in
adult patients receiving BTZ on days 1, 4, 8, and 11.30
Taken together, the data indicate that BTZ was metabo-
lized similarly to chemotherapy naïve patients.
3.4 | Combination BTZ and TMZ is well
tolerated
Sequential therapy with BTZ and TMZ was safe, well
tolerated and thrombocyte levels consistently normalized
by day 22 of each cycle (Figure 2B and Table 3).
FIGURE 2 Clinical, radiological and quality of life response. A, Pharmacokinetic analysis of bortezomib concentration (ng/mL)
in plasma of patients following five timepoints on day 1 and 7 of treatment. B, Thrombocyte counts during the first three treatment
cycles. Data represent the mean ± SEM from n= 10 patients. C, Density scores for perception of overall health on EQ‐5D‐5L
questionnaire. D, Correlation of self‐reported overall health and levels of pain on EQ‐5D‐5L. E, Swimmer plot of individual patients
depicting treatment start/stop times of all trial patients, aligned according to their first surgery. Bars represent survival in months
from first surgery, first and second MRI progression. Rightward arrow indicates that the patient was still alive at the time of final data
collection
RAHMAN ET AL. | 347
There was no dose limiting toxicity and most adverse
events were mild to moderate in severity (grades 1 or 2).
Only 6/10 patients reported toxicities that included grade
2 fatigue (3/10 patients: 30%) where in one patient it was
worsening of pre‐existing fatigue. Grade 2 pruritus and
urticaria was experienced by 1/10 patient (10%), while
grade 1 paresthesia, nausea, gastrointestinal infection,
intracranial hemorrhage, and diarrhea/constipation were
recorded in 5/10 (50%) patients, respectively (Table 3).
3.5 | Pain had greatest impact on self‐
reported quality of life
We used the EQ‐5D‐5L questionnaire to detect clinically
relevant differences in health‐related quality of life and
sought to identify variables that most predicted the
patients' general quality of life. The patients' overall
health evaluations were skewed towards higher values
indicating generally good perceived health (Figure 2C).
However, unadjusted analyses showed a significant re-
lation between overall health perception and usual
activities of daily living (b‐coefficient, −18.26; 95% con-
fidence interval [CI] [−30.904 to −5.020]; P= .005). An
increase of pain perception by one point on the EQ‐5D‐5L
was associated with 17 times reduced overall health
assessment (b‐coefficient, −17.592; 95% CI [−24.909 to
TABLE 3 Observed adverse eventsAny grade Grade 1 Grade 2
Adverse events n % n % n %
Fatigue 3/10 30 0 0 3/10 30
Nausea 1/10 10 1/10 10 0 0
Constipation 1/10 10 1/10 10 0 0
Pruritus 1/10 10 0 0 1/10 10
Paresthesia 1/10 10 1/10 10 0 0
Urticaria 1/10 10 0 0 1/10 10
Vomiting 1/10 10 1/10 0 0 0
Gastrointestinal infection (suspected) 1/10 10 1/10 0 0 0
Intracranial hemorrhage 1/10 10 1/10 0 0 0
Diarrhea 1/10 10 1/10 0 0 0
Thrombocytes 8/10 80 8/10 80 0 0
Total number of patient with adverse
events
6/10 60 5/10 50 4/10 40
Adverse events due to BTZ treatment 3/10 30 2/10 20 1/10 10
Adverse events due to TMZ treatment 5/10 50 1/10 10 4/10 40
Worsening of a pre‐existing condition 2/10 20 1/10 10 1/10 10
Note: Bold values indicate percentage.
TABLE 2 Estimated bortezomib concentration in plasma at
day 1 and 7 in patients receiving BTZ at day 1, 4, and 7
Day 1 Day 7
Patient ID Cmax AUC Cmax AUC
P01 6.10 460.2 19.35 2403.7
P02 5.56 1178.2 16.17 2845.3
P03 15.47 2344.6 15.14 2071.0
P04 6.37 889.8 14.52 1883.7
P05 7.76 1068.3 16.05 2538.4
P06 4.43 1096.9 10.97 2189.9
P07 5.51 1125.2 14.19 1818.6
P08 9.42 1403.1 14.39 2738.8
P09 13.37 1513.8 18.80 2985.6
P10 11.37 2159.9 25.90 4015.3
Average 8.54 1324.0 16.55*** 2549.0***
STD 3.748 701.90 4.059 380.43
Note: Plasma concentration at t= 0 hour (Cmax) and AUC at day 1 and 7 in
10 patients receiving BTZ at day 1, 4, and 7.
Abbreviation: AUC, area under the curve; STD, standard deviation
***Denotes significance at P< .001, respectively, using two‐sided Student's t
test to compare mean Cmax or AUC from day 1 and 7.
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−10.276]; P< .001). Likewise, perceived increased anxi-
ety or depression was greatly correlated with diminished
overall health assessment (b‐coefficient, −13.2048; 95%
CI [−22.842 to −3.254]; P= .009). We next performed a
stepwise analysis to determine which variable had the
most significant impact on patients' overall health per-
ception and found that pain (b‐coefficient, −13.293; 95%
CI [−18.567 to −8.019]; P< .001) and ability to perform
usual activities (b‐coefficient, −11.309; 95% CI [−15.090
to −7.528]; P< .001) had the most impact (Figure 2D).
However, the time point of the patients' pain experience
was not significant (b‐coefficient, 1.628; 95% CI [0.002‐
3.255]; P= .050) indicating that this was not associated
with their study participation. Moreover, analysis of in-
dividual effects of mobility (P= .001), self‐care (P= .003),
ability to perform usual daily activities (P= .001), pain
(P< .0001), depression/anxiety (P= .012) all showed in-
verse association with KPS. Median KPS after second
evaluation was 80 (range, 70‐100) and 80 (range, 60‐90) at
the third evaluation. In stepwise adjusted analyses, self‐
care (b‐coefficient, −4.893; 95% CI [−9.654 to −0.132];
P= .044) and ability to perform usual daily activities
(b‐coefficient, −4.39; 95% CI [−6.967 to −1.826]; P= .001)
were most correlated with KPS. Furthermore, stepwise
adjusted correlation analyses of NANO scale variables
with KPS, revealed inverted association of vision
(P= .020), strength (P< .0001), ataxia (P< .0001), and
language (P= .010) with KPS, however, ultimately, the
ability to perform usual daily activities (b‐coefficient,
−3.587; 95% CI [−5.534 to −1.640]; P< .0001), ataxia
(b‐coefficient, −14.03; 95% CI [−21.554 to −6.514];
P< .0001), and strength (b‐coefficient, −8.587; 95% CI
[−14.896 to −2.278]; P= .008) had the greatest effect
on KPS.
3.6 | Clinical and radiological responses
As of April 2020, 10 patients met the RANO radiological
or clinical progression criteria, eight were withdrawn
after two cycles. Two patients completed three and six
cycles of treatment. Of these 10 patients, eight died of
tumor progression while on second line treatment or
after study medication was discontinued (Figure 2E and
Table 1). After study treatment withdrawal five patients
(P01, P03, P05, P07, P08) were transitioned to lomustine
or the combination lomustine, avastin and vincristine
(LAVA), whereas four patients did not receive further
anti‐neoplastic treatment, (P02, P04, P09, P10; Table 1).
Notwithstanding, patient‐02 was alive for 4.5 months
after study withdrawal without further anti‐neoplastic
treatment, before his death. Patient‐03 had radiological
stable disease according to RANO criteria after the
second cycle and completed the six cycles of treatment
(Figures 2E and 3A). After a treatment break, he had a
third MRI progression, and received reirradiation and
lomustin and continued lomustine every 6th week. He
died 14.5 months after inclusion in the BORTEM‐17
study and had overall survival of 33.8 months. Patient‐05
and ‐07 are still alive and have survived 14.4 and 10.6
months, respectively, post recruitment. No problems of
noncompliance were recorded. After recruitment, med-
ian survival of the 10 patients was 5.2 months and
median overall survival was 21.4 months (Table 1).
3.7 | Slower tumour growth kinetics in
group 1 patients with positive MRI and
clinical responses
The patients were grouped a priori based on clinical or
MRI progression, where group 1 patients (01, 02, and
03) were characterized by long survival, stable clinical
symptoms and/or MRI confirmed stable disease dur-
ing BORTEM‐17 treatment. Group 2 patients (04, 07,
08, and 10) exhibited rapid clinical deterioration and
MRI confirmed progressive disease, while group 3
patients (05, 06, and 09) exhibited mixed positive and
negative clinical and radiological effects that did not
fit the profiles of neither group 1 nor group 2. The
median TMZ dose received for group 1, 2, and 3 pa-
tients was 150, 175, and 175 mg/m2, respectively.
Patient‐03 from group 1 had a left splenium contrast
enhancing lesion and achieved clinical and radi-
ological stable disease (20% progression from baseline
according to RANO criteria) 56 days after commen-
cing treatment (Figure 3A), subsequently completing
all six therapy cycles. However, volumetric quantifi-
cation of contrast enhancing tumour growth on 3D T1
weighted MRI revealed overall change of growth over
time in all patients (b‐coefficient, 12 403.7; 95% CI
[4880.8‐19 926.7]; P = .001; Figure 3B). Mean‐ tumour
volumes between the groups were not statistically
different, although compared to baseline volumes,
there was significant change after 112 days
(b‐coefficient, 24 220; 95% CI [−6435.8‐42 004.2];
P = .008) and 168 days (b‐coefficient, 30 828.4; 95%
CI [7512.3‐54 144.6]; P = .01) in group 1 patients.
Likewise, group 2 patients' MRI‐tumour volumes after
56 days were significantly different from group 1
baseline volumes, (b‐coefficient, 43 825.6; 95% CI
[14 670.8‐72 980.4]; P = .003). Group 1 patient tu-
mours exhibited the slowest growth rate indicated by
longest population doubling time (approximately
107.4 days) compared to group 2 and 3 patient tu-
mours (47.1 and 35.1 days, respectively; Figure 3C).
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3.8 | Immunological mechanisms of
patients with positive clinical responses
BTZ‐induced tumour death generates immunogenic
antigens and sensitizes to dendritic cell immuno-
therapy.24,31,32 Thus, we investigated the patients' T cell
activation and maturation status in blood and cytokines
circulating in their plasma at baseline, after exposure to
BTZ only (within the first 8 hours after administration),
BTZ + TMZ (on days 4‐7) and during the 3 weeks re-
covery period (days 11, 15, and 22) in cycle 1. We also
investigated responses to stimulation with PMA/iono-
mycin or autologous tumour cells ex vivo of patients'
PBMCs obtained at baseline (BTZ naïve) versus those
obtained during recovery (day 22‐56) after initial ex-
posure to BTZ + TMZ.
Remarkably, group 2 patients had substantially
higher levels of multiple immune tolerising Th2 cyto-
kines in plasma compared to group 1 and 3 patients.
During BTZ + TMZ treatment fourfold to sevenfold
higher concentrations of interleukin 4 (IL‐4) was ob-
served in group 2 compared to group 3 patients (P< .05;
Figure 4A). Group 2 patients also had consistently higher
IL‐5/IFNγ and IL‐4/IFNγ ratios (P< .05) from baseline
throughout treatment compared to group 3 patients. In
contrast, group 3 patients had threefold higher IL‐10
plasma levels compared to group 1 and group 2 patients
during BTZ and TMZ treatment (two way ANOVA,
P< .0001 and P< .001, respectively; Figure 4A), implying
a tolerising effect of TMZ chemotherapy through IL‐10,
in particular for group 3 patients.
3.9 | Rapidly progressing patients are
characterized by Th2 immune responses
and tolerised CD8+ T cell phenotype
Given their profound Th2‐cytokine driven anti‐
inflammatory responses, we investigated their relative
expression of cytotoxic T‐lymphocyte–associated antigen
4 (CTLA‐4) and programmed death 1 (PD‐1) immune
checkpoints on CD4+ and CD8+ T cell subsets
(Figure 4B‐F) as an indication of negative immune reg-
ulation and T cell exhaustion. Although there were no
significant differences in numbers of CD4+CTLA‐4+
T cells at baseline (Figures 4C and 4E), CD4+CTLA‐4+
T cells were increased by twofold to threefold after BTZ
and during combination with BTZ and TMZ in the ra-
pidly progressing group 2 patients compared to group 1,
(Figures 4C and 4E; one way ANOVA, P< .01, P< .05)
respectively, and compared to group 3 patients, (P< .05,
respectively). PD‐1+ CD4+ T cells were increased by
twofold to fourfold in group 2 compared to group 1
patients during combination BTZ with TMZ and later,
FIGURE 3 Tumour growth and population doubling time. A, Coregistered 3D T1 weighted gadolinium contrast enhanced serial
MR image of patient‐03 (IDHwt; MGMT UM, 54 years male) treated for 6 months, time indicated in days and tumour volume in µL.
B, Mean of 3D measured tumour volumes in mm3 from T1‐weighted MR images with contrast of all patients, and (C) tumor
population doubling time (in days) for group 1, 2, and 3 patients
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FIGURE 4 Immune mechanisms and augmented differentiation of CD4+ and CD8+ T cell subsets in patients with positive
clinical responses. A, Cytokine concentrations in pg/mL in patients' plasma, (top panels) IL‐4 and IL‐10, and (bottom panels) the
ratio between the average concentrations of IL‐5 and IL‐4 against IFNγ during treatment. B, Representative dot plots showing
(from left to right) patient NK and T cell lymphocytes in CD56 vs CD3 gates, CD8+ vs CD4+ T cell subsets and CD3+CD4+ T cells
expressing CTLA‐4. C, Representative dot plots showing CD3+CD4+ T cell subsets expressing CTLA‐4 and (D) Representative dot
plots showing CD3+CD8+ T cell subsets expressing PD‐1. E, Mean ± SEM % of CD3+CD4+ T cells expression of PD‐1 and CTLA‐4 in
group 1, 2, and 3 patients before, during and after treatment with BTZ and TMZ. F, Mean ± SEM % of CD3+CD8+ expressing
PD‐1 and CTLA‐4 before and after treatment with BTZ and TMZ. G, Dot plots showing CCR7 vs CD45RO within CD3+CD4+ T cell
subsets in group 1, 2, and 3 patients, before and during treatment with BTZ and TMZ. H, Mean ± SEM % expression of naïve (N),
effector (E), central memory (CM) and effector memory (EM) CD4+ T‐cells, and (I) CD4+ T‐effector cells before, during and after
treatment with BTZ and TMZ in group 1, 2, and 3 patients. *P< .05, **P< .01, ***P< .001, ****P< .0001, n= 10 patients. BTZ,
bortezomib; IFNγ, interferon γ; IL, interleukin; NK, natural killer; TMZ, temozolomide
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during recovery (one way ANOVA, P< .0001, both,
Figures 4C and 4E). Group 3 patients also upregulated
numbers of PD‐1+ CD4+ T cells by twofold to fourfold
compared to group 1 patients (one way ANOVA,
P< .0001, Figures 4C and 4E) during combination BTZ
with TMZ when IL‐10 levels were elevated in their
plasma (Figure 4A) and in the recovery period,
respectively.
Larger fractions of cytotoxic CD8+ T cells from group
2 patients expressed CTLA‐4 compared to group 1 pa-
tients at baseline (one way ANOVA, P< .01), during BTZ
(P< .0001), also after combination BTZ with TMZ treat-
ment (one way ANOVA, P< .0001) and during recovery,
(P< .001; Figure 4F). Group 2 patients also had higher
levels of CD8+ CTLA‐4+ T cells compared to group 3
patients during BTZ (one way ANOVA, P< .01), at
combination BTZ with TMZ treatment (P< .01;
Figure 4F). Collectively, these data might indicate that
CD4+ T cells from the rapidly progressing patients are
biased towards a Th2 phenotype and tolerised at earlier
stages (days 1‐7 of BTZ, as well as BTZ + TMZ treatment).
This is consistent with the profound Th2 cytokine pro-
files in their plasma. On the other hand, CD8+ effector T
cells from rapidly progressive and mixed benefit patients
from group 2 and 3, respectively, upregulated the in-
hibitory receptor PD‐1 (Figures 4D and 4F) only at later
stages during recovery (days 4‐15.) Importantly, this
phenomenon was not evident in group 1 patients.
3.10 | Augmented differentiation of
CD4+ and CD8+ T cell subsets in patients
with positive clinical responses
Given the potential tolerization and exhaustion of T cells
denoted by differential Th2/Th1 cytokine ratios and ex-
pression of PD‐1 and CTLA‐4 checkpoint molecules in
the patients undergoing treatment, we sought to in-
vestigate their maturation phenotypes. We used CCR7,
CD45RO, CD28 surface expression to discriminate dis-
tinct differentiation stages from naïve (TN), effector (TE),
central memory (TCM), effector memory (TEM), and
NK‐cells (Figures 4G and S2). While there was no dif-
ference in differentiated CD4+ T cell subsets between
patients at baseline, group 1 patients with positive clin-
ical and immunological responses had increased CD4+
TE subsets after BTZ + TMZ combination treatment
compared to rapidly progressive group 2 and 3 patients
(two way ANOVA, P< .001, respectively (Figure 4G,H)
and during the recovery period (two way ANOVA
P< .05; Figure 4G,H). Importantly, CD4+ TE subsets were
not only increased after BTZ+ TMZ treatment within
group 1 patients, but also during recovery compared to
baseline (two way ANOVA, P< .05, both), and BTZ only
treatment, (Figure 4I; two way ANOVA P< .01 and
P< .05, respectively). Correspondingly, these patients
had fewer CD4+ TCM during combination BTZ + TMZ
treatment and recovery periods (one way ANOVA,
P< .05, and P< .01), respectively (Figure 4H). These data
indicate that the group 1 patients with positive clinical
and Th1 driven immune responses possibly mobilized
and expanded CD4+ TE subsets in response to novel an-
tigens produced as a result of BTZ + TMZ induced tumor
cell death.
3.11 | Patients with positive clinical
responses diminish CTLA‐4+ CD4+T cells
and attenuate IL‐10 secretion after
treatment
To investigate whether the Th2‐biased and tolerised T
cell phenotype before and after BTZ treatment in some
patients could be reversed, we used PMA/ionomycin to
stimulate PBMCs isolated from patients' blood at baseline
and on day 22 during recovery after exposure to BTZ and
TMZ therapy. Stimulation of baseline PBMCs with PMA/
ionomycin increased the level of CTLA‐4+CD4+ Th cells
in group 2 and 3 patients by sixfold compared to group 1
patients (Figure 5A,B, two way ANOVA, P< .0001, re-
spectively), and CTLA‐4+CD8+ T cells by threefold
(group 2 vs 1, P< .001; Figure 5C). However, stimulation
of PBMCs that had been exposed to BTZ + TMZ treat-
ment in situ induced the greatest numbers of CTLA‐4+
expressing CD4+ Th cells in group 3, compared to both
group 1 and 2 patients (Figure 5B, two way ANOVA
P< .0001), respectively. Notably, stimulation of PBMCs
from rapidly progressing group 2 patients exposed to
BTZ+ TMZ treatment diminished the fractions of
CTLA‐4+ CD4+ Th cells by ca. 15% (Figure 5B) compared
to stimulation at baseline, implying positive effects of the
treatment, also indicated by diminishing immune sup-
pressive Th2/Th1 cytokine ratios in plasma after treat-
ment (Figure 4A). CD8+ T cell subsets from group 1
patients had moderate levels of intracellular interferon
γ (IFNγ) compared to group 3 patients stimulated at
baseline or during treatment recovery (two way ANOVA
P< .05 respectively, Figure 5D,E). Correspondingly,
group 3 patients with greatest fractions of CTLA‐4+CD4+
Th cells also exhibited greater immunosuppressive IL‐10/
IFNγ ratios at recovery compared to both group 1 and
group 2 patients (P< .0001, respectively; Figure 5F).
Confirming the profound immune suppressive and
Th2‐driven responses, also observed in plasma cytokines,
unstimulated PBMCs from both group 2 and 3 patients
exhibited greater IL‐10/TNF‐α at recovery compared to
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group 1 patients (P< .05, respectively; Figure 5G), and
IL4/TNF‐α ratios in unstimulated PBMCs at baseline
compared to group 1 patients (P< .001, respectively;
Figure 5H). In patient‐02 from group 1 whose tumour
was available for coculture with autologous PBMCs, the
CD8+T cells were not tolerised by coculture with the
tumour, compared to PBMCs not cocultured with tumour
cells, or PBMCs stimulated with PMA/ionomycin (one
way ANOVA, P< .0001, Figure 5I). Robust stimulation
with PMA/ionomycin increased CD107a degranulation
in CD8+ T cells compared to PBMCs exposed or not to
BTZ in situ or cocultured with patient‐02' autologous
tumour cells (P< .05). Nevertheless, release of cytolytic
granzyme B by CD8+ T cells was least potent upon co-
culture with autologous tumour cells (P< .0001) com-
pared to BTZ naïve PBMCs (Figure 5I). IL‐2 secretion was
greatest after stimulation with PMA/ionomycin of
PBMCs at baseline and after BTZ exposure (P< .001;
Figure 5J). Although attenuated, cytotoxic CD8+ T cells
increased tumour necrosis factor α (TNF‐α) secretion
when exposed to autologous patient‐02' tumour cells and
when compared to unstimulated PBMCs from baseline
(P< .01), at day 22 during recovery after BTZ + TMZ
treatment (P< .05) and at day 56 post treatment
(P< .001; Figure 5K). Collectively, these data might in-
dicate that this patient's killer T cells were able to launch
appropriate responses against his tumour ex vivo.
3.12 | BTZ induced NK cell maturation
phenotype and expression of inhibitory
checkpoints
Group 1 patients possessed more mature CD16+CD57+
NK cells at baseline (P< .01), during BTZ (P< .05),
BTZ + TMZ treatment (P< .01) and during recovery
(P< .05) compared to group 3 patients, and during
BTZ+ TMZ (P< .05), and recovery (P< .0001) compared
to group 2 patients (Figure 2A‐2E). Surprisingly, these
mature subsets in the group 1 patients upregulated the
inhibitory checkpoint receptors NKG2A and PD‐1
(Figure S2F,S2G), and diminished activating DNAM‐1
and CD69 receptors (Figure S2H,S2I). In contrast, during
BTZ+ TMZ treatment group 2 and 3 patients who se-
creted high levels of IL‐10 and had less profound T cell
responses also decreased CD16+CD57+ mature NK cell
fractions compared to group 1 patients (CD16: group 2 vs
1, P< .05; group 3 vs 1, P< .01) and CD57: group 2 vs 1,
P< 0.01; group 3 vs 1, P< .05). Within the reduced
CD16+ CD57+ NK cell fractions in group 2 and 3 patients
(Figure S2D,S2E) inhibitory NK cells expressing NKG2A
and PD‐1 were also diminished compared to group 1
patients (Figure S2F,S2G), whereas subsets expressing
DNAM‐1 and CD69 were increased after BTZ and TMZ
treatment (Figure S2H,S2I), potentially indicating in-
creased activation.
Taken together, copious IL‐10 levels in plasma may
have contributed to greater activation of their NK cells
but attenuated T cell responses after BTZ and TMZ
treatment. Unfortunately, due to limited PBMCs and lack
of access to fresh biopsy tissue for all patients, we could
not perform functional assays with purified NK cells to
mechanistically interrogate these findings.
4 | DISCUSSION
We sought herein to investigate as primary objective
whether sequential pretreatment with BTZ to sensitize
recurrent GBM patients with unmethylated MGMT pro-
moter to TMZ chemotherapy was safe and tolerated. This
is because previous analyses utilized a concurrent
FIGURE 5 PBMCs from patients with positive clinical responses diminish CTLA‐4+ CD4+Th cells, attenuate IL‐10 secretion and
have moderate intracellular IFNγ after bortezomib + temozolomide treatment. A, Representative dot plots showing CD4 vs CTLA‐4
in patient PBMCs unstimulated and stimulated, with PMA/ionomycin before or after exposure to BTZ or BTZ + TMZ treatment in
situ. B, Mean ± SEM % of CD4+ CTLA‐4+ T cells at baseline or after treatment/stimulation conditions in group 1, 2, and 3 patients. C,
Mean± SEM % of CD8+ CTLA‐4+ at baseline or after treatment/stimulation conditions in group 1, 2, and 3 patients. D Representative
dot plots showing intracellular IFNγ in CD8+T cells in patients' PBMCs unstimulated and stimulated with PMA/ionomycin in
group 1 vs 2 patients. E, Mean± SEM % of CD8+ IFNγ+ T cells at baseline or after treatment/stimulation conditions in group 1, 2, and
3 patients. Cytokines present in supernatants from patients' PBMCs after stimulation with PMA/ionomycin represented as mean± SEM
of Th2/Th1 ratio between (F) IL‐10 and IFNγ, (G) IL‐10 and TNF‐α, and (H) IL‐4 and TNF‐α in group 1, 2, and 3 patients at baseline
or during treatment recovery. I, Mean± SEM % expression of markers in patient‐02 tumour or PBMCs unstimulated and stimulated
with PMA/ionomycin or P02‐tumour before or after exposure to bortezomib+ temozolomide in situ. Cytokine concentrations in pg/mL
from supernatants from patient‐02 tumour or PBMCs unstimulated or stimulated ex vivo with PMA+ ionomycin or patient‐02 tumour or
before and after exposure to bortezomib+ temozolomide in situ of (J) IL‐2 and (K) TNF‐α. *P< .05; **P< .01; ***P< .001: ****P< .0001,
n= 10 patients. BTZ, bortezomib; IFNγ, interferon γ; IL, interleukin; TMZ, temozolomide; TNF‐α, tumor necrosis factor α
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schedule with monotherapy BTZ, metronomic doses of
TMZ, or were conducted in newly diagnosed patients.33‐37
In this phase IB study, we successfully dose escalated
TMZ to the target 200mg/m2 dose for combination with
1.3 mg/m2 BTZ and no grade 3 or 4 toxicities were re-
gistered in our study. This is consistent with previous
trials using concurrent schedules22 with intensive and
prolonged treatment, as well as with various drug com-
binations.33‐39
Our patients scored relatively high on the quality of
life EQ‐5D‐5L questionnaire that was previously vali-
dated for the Norwegian population.40 The ability to
perform usual daily activity, ataxia, and changes in
strength were the strongest predictors of KPS and this
finding is corroborated by a previous study of Norwegian
patients after surgery.41 BTZ crosses the blood brain
barrier in human and mice22,39 and higher concentra-
tions were found in brain tissue than in plasma.39 Our
pharmacokinetic analysis showed similar rapid redis-
tribution of the drug from plasma to tissue as was re-
ported for newly diagnosed patients.29,30
Nevertheless, the BORTEM‐17 patients segregated a
priori into three groups based on clinical and/or radi-
ological progression. The grouping was concordant with
tumor growth characteristics where group 2 patients with
the most rapid progression had the greatest tumour burden
(ca. 34 × 103mm3) at baseline. Moreover, their tumour
population doubling time from baseline to first MRI eva-
luation at day 56 was 47.1 days, nearly twofold faster than
the group 1 patients whose baseline tumour volume was
ca. 17.2 × 103mm3 and had a prolonged doubling time of
107.4 days. Although two‐thirds patients in groups 1 and 3
had prior treatment with stereotactic radiosurgery (SRS)
after their second recurrence and before study recruitment,
these patients had differential clinical responses. To mini-
mize the challenge of differentiating tumour recurrence
from radiation necrosis, study recruitment was based on
MR contrast enhancing lesion greater than or equal to
12 weeks after completed radiotherapy. Furthermore, the
SRS treated lesions were not considered as target lesions in
the RANO evaluation of tumour progression.
IDH1 mutant genotype is associated with improved
outcome10,42 but 2/3 (66%) of best performing group 1
patients had wt IDH1 compared to 2/4 (50%) and 2/3
(66%) patients from group 2 and 3, respectively. Since the
IDH‐status had similar heterogeneous frequency within
the groups, this was therefore not considered the un-
derlying cause for differential responses of the patients.
Furthermore, nine of the 10 patients had de novo GBM,
with no evidence of a less malignant lesion before GBM
diagnosis. Patient 07's IDH1‐mutant GBM tumor had
progressed from an initial grade III anaplastic astro-
cytoma, thus representing a secondary GBM. Thus, the
primary vs secondary GBM status also could not explain
the differential prognosis between the patient groups. We
did not however, classify the tumors based on previously
reported gene expression profiles43‐46 because we only
had access to formalin fixed paraffin embedded tumor
tissue. Three molecular GBM subtypes termed proneural,
proliferative, and mesenchymal44 were identified and
reported to have prognostic value that was independent
of the World Health Organization histological grading
and/or presence of necrosis. Further subclassifications
identified four subtypes–classic, mesenchymal, proneur-
al, and neural signatures45,46 and now, more recently,
greater heterogeneity at the cellular level was con-
firmed.43 However, the proneural GBM subtype with
assumed good prognosis in the Phillip et al's44 study was
associated with poor prognosis in the Verhaak study.45
Furthermore, the subtypes coexist and vary spatially
within the individual tumors as shown by multiregional
sampling. Longitudinal analyses also indicate that the
subtype signatures may change over time, affected, for
example, by therapy. Thus, although the molecular sub-
types provide great insight and opportunities for targeting
therapies to the aberrant gene pathways, they fail to de-
monstrate robust differences in survival between them
and are thus, not currently utilized clinically for diag-
nosis or prognostication. For this reason, we did not
classify the tumors according to these molecular
subtypes.
Remarkably, group 2 patients who also exhibited
profound tolerance within their peripheral immune cell
compartments demonstrated by dominant Th2 vs. Th1
suppressive cytokine ratios in plasma, consistently ele-
vated PD‐1 and CTLA‐4 immune checkpoints on both
CD4+ Th and CD8+ cytotoxic T cells throughout the
treatment. They also had fewer fractions of CD16+CD57+
mature NK cells and subsets expressing inhibitory
NKG2A and PD‐1 checkpoint molecules. In contrast,
NK‐ cell populations expressing CD69 and DNAM‐1 were
increased after BTZ and TMZ treatment, potentially in-
dicating increased activation. Indeed, when BTZ naïve
PBMCs from group 2 patients were stimulated with
PMA/ionomycin ex vivo, they responded by secreting
suppressive Th2 cytokines such as IL‐4, IL‐10 and upre-
gulated CTLA‐4+CD4+ and CTLA‐4+CD8+ T cell frac-
tions. Under the influence of IL‐4, tumor cells secrete
IL‐10 which hinders activation and recruitment of
adaptive immune mediators to the tumor microenviron-
ment, by for example, downregulating CD28 expression,
inhibiting proliferation and secretion of Th1 cytokines
(IFNγ, TNF‐α, IL‐2) by T cells, as well as counteracting
antigen presentation by dendritic cells.47,48 IL‐10 also
diminishes tumor cell expression of class I major
histocompatibility molecules (MHC),49 and provides
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opportunity for NK cell mediated cytotoxicity. IL‐10 thus
also regulates NK cell cytotoxicity and is established to
have a dual pro‐ and anti‐inflammatory role in different
cell types and under different conditions.50 IL‐10 gene
polymorphisms that reduce IL‐10 levels correlate with
increased melanoma incidence, while high IL‐10 levels
are observed at sites of spontaneous rejection in primary
melanoma,51 potentially NK cell mediated. Intravenous
administration of IL‐10 to healthy volunteers induced
increased IFN‐γ and granzyme release.52 IL‐10 con-
ditioning of NK cells in vitro upregulated mRNA tran-
scripts for type I interferons, high mobility group 1, CD69
and secretogranin 1 (TIA‐1) molecules and increased NK
cytotoxicity against resistant Daudi cells.53 Thus, while
mediating tolerance and escape from adaptive immunity,
IL‐10 cytokine may promote NK cells' antitumor activity
in early stages. Thus, the rapid progression and high le-
vels of IL‐10 secreted by group 2 and group 3 patients
after BTZ+ TMZ treatment may have acutely induced
their activated NK cell phenotype.
However, such a substantial Th2 immune response is
likely to down‐regulate tumor‐specific Th1 and CD8+T
cell responses54 in the long run and contribute to tumor
immune evasion and cancer progression in these pa-
tients. CTLA‐4 expression would further decrease T cell
activation, proliferation and effector functions.55,56 In
contrast, group 1 patients with lower disease burden and
slower tumor growth kinetics had less suppressive Th2
driven cytokine responses and specifically IL‐10, and
expanded CD4+ effector T cells in response to treatment.
We speculate that this reflects beneficial Th1 and CD8+
T cell mediated antitumor responses enhanced by
BTZ + TMZ combination therapy, possibly due to en-
hanced tumor antigen presentation.
Surprisingly, group 3 patients with mixed clinical/
radiological responses had the lowest tumor burden (ca.
5.5 × 103 mm3) yet exhibited the most rapid population
doubling time of 35.1 days. These patients also had
multiple neoplastic lesions. In response to BTZ + TMZ
treatment, group 3 patients secreted the highest con-
centrations of immunosuppressive IL‐10 cytokine in
plasma and exhibited a tolerogenic phenotype (partially
overlapping with the group 2 patients) denoted by upre-
gulated PD‐1+CD4+ and CTLA‐4 +CD8+ T cell subsets
compared to group 1 patients. TMZ can suppress immune
responses in some glioma patients as it has been shown
to downregulate activation of the JAK/STAT pathway
and induce PD‐L1 expression on tumor cells.57
Although group 2 and 3 patients responded to PMA/
ionomycin stimulation by secreting high levels of the
IFNγ Th1 cytokine, their levels of IL‐10 were many
magnitudes higher, culminating in an overall immune
suppressive phenotype. These data might indicate that
the tolerant phenotype is not simply a feature of high
tumor burden but may reflect tumor cell intrinsic fea-
tures as the tumor leverages multipronged strategies to
escape immune detection and destruction.58 The caveat
to this study is the small sample size and lack of rando-
mized controls as it was powered primarily for evaluation
of safety and tolerance of sequentially combined BTZ
with dose escalated TMZ, as well as radiological and
immunological biomarker analyses. The latter was chal-
lenged by the unavailability of sufficient ex vivo PBMCs
for NK cell isolation and fresh autologous tumor cells
from all patients for functional assessment.
Nevertheless, cytokine signaling locally in the brain
cross‐talks with that in the systemic circulation, and
aberrant function is often reflected in unison with phe-
notypic defects. In conclusion, 3 of 4 patients in group 2
were recruited into the BORTEM‐17 trial after their first
tumor recurrence and this distinguished them from both
group 1 and group 3 patients where all patients were
recruited after their second recruitment. Group 1 patients
further distinguish from both group 2 and group3 by
diminished IL‐10 levels. Thus, levels of IL‐10 after
BTZ+ TMZ treatment could be monitored prospectively
as a potential biomarker for probability of immunological
responses defining the patients as group 1‐, 2‐, or 3‐type.
Combination BTZ + TMZ treatment was safe, tolerated
and immunological and MRI biomarkers provided robust
indication for best responder patients exhibiting Th1
driven immune responses.
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